Mesoblast (ASX:MSB) Selling, General, & Admin. Expense: A$0.00 Mil (TTM As of Dec. 2025)


ASX:MSB Mesoblast Ltd ASX:MSB
40 GF Score
Price A$2.24
! 4 Warning Signs
View Full Analysis

What is Mesoblast Selling, General, & Admin. Expense?

Mesoblast ASX:MSB +6.67% 40 Selling, General, & Admin. Expense is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 40/100. The stock has 4 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Mesoblast's selling, general, & admin. expense for the three months ended in Dec. 2025 was A$0.00 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.


Mesoblast  (ASX:MSB) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Mesoblast Selling, General, & Admin. Expense Related Terms


Mesoblast Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Mesoblast's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Selling, General, & Admin. Expense Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.17 82.49 40.95 37.62 60.38

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:MSB vs VRTX, REGN, ALNY: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Mesoblast's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Mesoblast's Selling, General, & Admin. Expense falls into.


ASX:MSB
40GF Score
Mesoblast Ltd ASX:MSB
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of A$0.00 Mil mean?
Mesoblast (ASX:MSB) has a Selling, General, & Admin. Expense of A$0.00 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Mesoblast and its competitors.
Is Mesoblast's Selling, General, & Admin. Expense too high?
Mesoblast's current Selling, General, & Admin. Expense is A$0.00 Mil. Overall, Mesoblast has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Selling, General, & Admin. Expense compare to VRTX and REGN?
Mesoblast's Selling, General, & Admin. Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Mesoblast and its competitors. Mesoblast's current Selling, General, & Admin. Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Selling, General, & Admin. Expense of A$0.00 Mil. The current Selling, General, & Admin. Expense is A$0.00 Mil. Mesoblast's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Selling, General, & Admin. Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
40GF Score

Get the complete analysis for ASX:MSB

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.24
Price